Cryopreserved ampule of negatively selected Human Peripheral Blood CD14+ Monocytes, containing ≥ 50 million cells
Human Peripheral Blood CD14+ Monocytes, Cryopreserved, Negative Selection, 10 million
Cryopreserved ampule of Human Peripheral Blood CD14+ Monocytes, negative selection, containing ≥10 million cells
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 25 million cells
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 1 million cells
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 5 million cells
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 10 Million
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing 10 million cells
-
Cryopreserved Human LeukopakA brief guide and introduction to Lonza Cryopreserved Leukopak
-
Custom Human Immune Cell Isolations Toss SheetA brief introduction to the services that Lonza CellBio Service can offer with regards to custom immune cell isolations.
-
Instructions - Cryopreserved Human Stellate CellsTechnical Instructions for culturing human stellate cells
-
Discover the Freshness of Frozen PBMCsAn Assessment of Cryopreservation Impact on T Cell Activation
-
Human CD34+ Cells Technical information and instructions for use
-
Cold Storage of Fresh Leukopak Maintains Cell Viability and FunctionalityLearn how advanced cold storage approaches enable optimal levels of product integrity, quality, stability and viability
-
Primary Blood and Immune Cells for ResearchPresentation (PDF) showcasing Lonza's portfolio and capabilities of primary blood and immune cells for research.
-
Cryopreservation of Peripheral Blood Mononuclear CellsDoes Not Alter Immune Cell Phenotype
-
The Cell and Gene Therapies Journey from Translation to CommercializationDownload our comprehensive eBook on how to accelerate cell and gene therapy development, from translation to GMP production and commercialization.
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cellsA strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.